CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study
Copyright policy )CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study
AbstractIntroductionThe aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta‐amyloid (Aβ1–42), phosphorylated tau, and total tau (tau) to discriminate Alzheimer's disease (AD) dementia from other forms of dementia.MethodsA total of 675 CSF samples collected at eight memory clinics were obtained from healthy controls, AD dementia, subjective memory impairment, mild cognitive impairment, vascular dementia, Lewy body dementia (LBD), fronto‐temporal dementia (FTD), depression, or other neurological diseases.ResultsCSF Aβ1–42 showed the best diagnostic accuracy among the CSF biomarkers. At a sensitivity of 85%, the specificity to differentiate AD dementia against other diagnoses ranged from 42% (for LBD, 95% confidence interval or CI = 32–62) to 77% (for FTD, 95% CI = 62–90).DiscussionCSF Aβ1–42 discriminates AD dementia from FTD, but shows significant overlap with other non‐AD forms of dementia, possibly reflecting the underlying mixed pathologies.
- University of Bonn Germany
- University of Gothenburg Sweden
- University of Geneva Switzerland
- Ludwig-Maximilians-Universität München Germany
- Assistance Publique -Hopitaux De Paris France
Male, Internationality, MAPT protein, human, tau Proteins, cerebrospinal fluid [Amyloid beta-Peptides], Sensitivity and Specificity, Spinal Puncture, Diagnosis, Differential, Alzheimer Disease, Humans, Biomarkers/cerebrospinal fluid, cerebrospinal fluid [Peptide Fragments], Phosphorylation, Aged, Aged, 80 and over, Amyloid beta-Peptides, diagnosis [Alzheimer Disease], Alzheimer Disease/cerebrospinal fluid/diagnosis, tau Proteins/cerebrospinal fluid, Middle Aged, amyloid beta-protein (1-42), Amyloid beta-Peptides/cerebrospinal fluid, Peptide Fragments, cerebrospinal fluid [Alzheimer Disease], cerebrospinal fluid [Biomarkers], cerebrospinal fluid [tau Proteins], Female, Peptide Fragments/cerebrospinal fluid, Biomarkers, ddc: ddc:610
Male, Internationality, MAPT protein, human, tau Proteins, cerebrospinal fluid [Amyloid beta-Peptides], Sensitivity and Specificity, Spinal Puncture, Diagnosis, Differential, Alzheimer Disease, Humans, Biomarkers/cerebrospinal fluid, cerebrospinal fluid [Peptide Fragments], Phosphorylation, Aged, Aged, 80 and over, Amyloid beta-Peptides, diagnosis [Alzheimer Disease], Alzheimer Disease/cerebrospinal fluid/diagnosis, tau Proteins/cerebrospinal fluid, Middle Aged, amyloid beta-protein (1-42), Amyloid beta-Peptides/cerebrospinal fluid, Peptide Fragments, cerebrospinal fluid [Alzheimer Disease], cerebrospinal fluid [Biomarkers], cerebrospinal fluid [tau Proteins], Female, Peptide Fragments/cerebrospinal fluid, Biomarkers, ddc: ddc:610
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).111 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!